Drug Profile
Anti-GATA3 gene therapy - Sterna Biologicals
Alternative Names: hgd40; SB-010; SB-011; SB-012Latest Information Update: 22 Nov 2022
Price :
$50
*
At a glance
- Originator sterna biologicals; University of Marburg
- Developer German Center for Lung Research; sterna biologicals
- Class Anti-inflammatories; Antiasthmatics; Antisense oligonucleotides; Catalytic DNA; Skin disorder therapies
- Mechanism of Action GATA3 transcription factor inhibitors; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Ulcerative colitis
Highest Development Phases
- Phase II Allergic asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Ulcerative colitis
Most Recent Events
- 22 Nov 2022 Anti-GATA3 gene therapy - Sterna Biologicals is available for licensing as of 22 Nov 2022. https://www.sterna-biologicals.com/pipeline
- 14 Dec 2021 Sterna Biologicals initiates enrolment in the phase IIa GIANT-1 trial in Asthma in Germany (Inhalation) (Sterna Biologicals pipeline, January 2022)
- 07 Jan 2021 Sterna Biologicals plans a phase I/IIb with SB 012 in Ulcerative colitis in the first half of 2023 (PO)